Adrienne D. Cox - Publications

Genetics & Molecular Biology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Genetics, Molecular Biology

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Papke B, Azam SH, Feng AY, Gutierrez-Ford C, Huggins H, Pallan PS, Van Swearingen AED, Egli M, Cox AD, Der CJ, Pecot CV. Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. Acs Pharmacology & Translational Science. 4: 703-712. PMID 33860195 DOI: 10.1021/acsptsci.0c00165  0.72
2020 Ozkan-Dagliyan I, Diehl JN, George SD, Schaefer A, Papke B, Klotz-Noack K, Waters AM, Goodwin CM, Gautam P, Pierobon M, Peng S, Gilbert TSK, Lin KH, Dagliyan O, Wennerberg K, ... ... Cox AD, et al. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports. 31: 107764. PMID 32553168 DOI: 10.1016/J.Celrep.2020.107764  0.72
2020 Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, ... ... Cox AD, et al. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine. PMID 32483362 DOI: 10.1038/S41591-020-0947-8  0.72
2020 Javaid S, Waters AM, Nguyen VV, Der CJ, Cox AD. Abstract B40: Role of mutant HRAS in growth and drug sensitivity of head and neck squamous cell cancers (HNSCC) Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B40  0.72
2020 Papke B, Swearingen AEDV, Feng AY, Azam SH, Harrison EB, Yang R, Cox AD, Der CJ, Pecot CV. Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B32  0.72
2019 Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, ... ... Cox AD, et al. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discovery. PMID 31771969 DOI: 10.1158/2159-8290.Cd-19-0811  0.72
2019 Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, ... ... Cox AD, et al. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery. PMID 31649109 DOI: 10.1158/2159-8290.Cd-19-1006  0.72
2019 Blake DR, Vaseva AV, Hodge RG, Kline MP, Gilbert TSK, Tyagi V, Huang D, Whiten GC, Larson JE, Wang X, Pearce KH, Herring LE, Graves LM, Frye SV, Emanuele MJ, ... Cox AD, et al. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science Signaling. 12. PMID 31311847 DOI: 10.1126/Scisignal.Aav7259  0.72
2019 Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, ... ... Cox AD, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine. PMID 30833752 DOI: 10.1038/S41591-019-0368-8  0.72
2019 Bryant KL, Klomp JE, Lee YS, Stalnecker CA, Grover KR, Edwards AC, Peng S, Pierobon M, Petricoin EF, Tran N, Kimmelman AC, Cox AD, Der CJ. Abstract PR10: Enhancing the effect of autophagy inhibition for pancreatic cancer treatment Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-Pr10  0.72
2019 Goodwin CM, Javaid S, Waters AM, Papke B, Yang R, Pierobon M, Freed DM, Roberts PJ, Cox AD, Wood KC, Petricoin EF, McRee AJ, Der CJ. Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-287  0.72
2019 Javaid S, Nguyen VV, Waters AM, Goodwin CM, Der CJ, Cox AD. Abstract LB-276: Farnesyltransferase inhibitor (FTI)-induced growth inhibition of HRAS-mutant head and neck cancers is enhanced by concurrently inhibiting compensatory upregulation of the ERK-MAPK kinase cascade Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-276  0.72
2019 Gautam P, Vähä-Koskela M, Tomlinson M, Cox AD, Der CJ, Aittokallio T, Wennerberg K. Abstract A137: Drug screening and molecular profiling identifies INKA1 as a predictive biomarker for sensitivity to MAPK inhibition-antimitotic combination treatment in pancreatic ductal adenocarcinoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A137  0.72
2018 Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, ... ... Cox AD, et al. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 34: 807-822.e7. PMID 30423298 DOI: 10.1016/J.Ccell.2018.10.001  0.72
2018 Cox AD, Goodwin CM, Bryant KL, Dagliyan I, George SD, Lucas KE, Gautam P, Wennerberg K, Der CJ. Abstract SY20-02: Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Sy20-02  0.72
2017 Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling. 10. PMID 28951536 DOI: 10.1126/Scisignal.Aao3332  0.72
2017 Justilien V, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, Murray NR, Fields AP. Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. Cancer Cell. PMID 28110998 DOI: 10.1016/J.Ccell.2016.12.010  0.72
2016 Zhou B, Der CJ, Cox AD. The role of wild type RAS isoforms in cancer. Seminars in Cell & Developmental Biology. PMID 27422332 DOI: 10.1016/J.Semcdb.2016.07.012  0.72
2016 Ryan MB, Finn AJ, Pedone KH, Thomas NE, Der CJ, Cox AD. ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-mutant Melanoma. Molecular Cancer Research : McR. PMID 27418645 DOI: 10.1158/1541-7786.Mcr-16-0184  0.72
2016 Zhou B, Ritt DA, Morrison DK, Der CJ, Cox AD. CK2alpha Maintains ERK Activity in a Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but not ERK in BRAF-mutant Melanoma. The Journal of Biological Chemistry. PMID 27226552 DOI: 10.1074/Jbc.M115.712885  0.72
2016 Ryan MB, Bryant KL, Hayes TK, Kher S, Wood KC, Samatar AA, Cox AD, Der CJ. Abstract 4660: Inhibition of p38 enhances ERK inhibitor efficacy in pancreatic ductal adenocarcinoma Cancer Research. 76: 4660-4660. DOI: 10.1158/1538-7445.Am2016-4660  0.72
2015 Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, ... ... Cox AD, et al. Long-term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. PMID 26725216 DOI: 10.1016/J.Ccell.2015.11.011  0.72
2015 Kidd AR, Muñiz-Medina V, Der CJ, Cox AD, Reiner DJ. The C. elegans Chp/Wrch Ortholog CHW-1 Contributes to LIN-18/Ryk and LIN-17/Frizzled Signaling in Cell Polarity. Plos One. 10: e0133226. PMID 26208319 DOI: 10.1371/Journal.Pone.0133226  0.76
2015 Cox AD, Der CJ, Philips MR. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1819-27. PMID 25878363 DOI: 10.1158/1078-0432.Ccr-14-3214  0.72
2014 Zhou B, Kassner M, Yin H, Der CJ, Cox AD. Abstract LB-217: CK2 protein kinase promotes resistance to MAPK pathway inhibition Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-217  0.72
2012 DeCristo MJ, Parker LE, Trembath D, Kuan P, Yim M, Liu J, Miller CR, Der CJ, Cox AD. Abstract LB-30: A functional analysis of the nuclear RhoGEF Ect2 in ovarian cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-30  0.72
2000 Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. The Journal of Biological Chemistry. 275: 30740-5. PMID 10900196 DOI: 10.1074/Jbc.M001702200  0.76
Show low-probability matches.